Gilead to Buy Cancer Biotech Tubulis in $5B Deal
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Gilead agreed to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development. (Source: Bloomberg)
Original Source
Read the full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.